Drugs / CD6-CAR Tregs
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07395050 | Sep 2026 expected | type 1 diabetes mellitus | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05993611 | Feb 2024 → May 2028 | chronic graft versus host disease, hematologic disorder | City of Hope Medical Center | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD6-CAR Tregs | “The investigational product is an autologous (patient-derived) anti-CD6 chimeric antigen receptor (CD6-CAR) T regulatory cell (Treg) cellular product (CD6-CAR Tregs).” NCT07395050 ↗1“allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs)” NCT05993611 ↗ |
| Known as | autoCD6-CAR Tregs | “This is a single-center, pilot clinical trial of autologous CD6-targeted chimeric antigen receptor regulatory T cells (autoCD6-CAR Tregs) in patients diagnosed with Type 1...” NCT07395050 ↗ |
| Modality | Cell therapy | “allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs)” NCT05993611 ↗ |
| Route | Intravenous | “Patients then receive CD6-CAR Treg intravenously on day 0.” NCT05993611 ↗ |
| Target | CD6 | “The gene for a special receptor that binds to a certain protein, CD6, on the patient's cells is added to the T cells in the laboratory.” NCT05993611 ↗ |